Download the highlights from our DCAT presentation to learn how continuous biomanufacturing reduces the environmental impact of antibody production.
The continuous manufacturing of therapeutic antibodies in agile facilities with a small cleanroom footprint allows:
- 67% reduction in facility footprint
- 50% less process water
- 65% less plastic waste
- 73% lower CO2 emissions
Just-Evotec Biologic's unique continuous biomanufacturing platform for antibody therapeutics and innovative J.POD facility design are reducing manufacturing costs and increasing the sustainability of bioproduction.
View the presentation to learn more!